Background and objective: Passiflora incarnata (passionflower) has traditionally been used to treat insomnia and anxiety. We recently reported that an aqueous ethanol extract of
Preclinical studies of passionflower extract (PFE) have demonstrated psychotropic effects in mouse behavioral models. Administration of PFE (approximately 400 mg/kg) to mice increased momentum in the unfamiliar environment test [8] and the elevated plus maze test [9] .
It has been suggested that GABA-sensitive neurons [10, 11] and an opioidergic mechanism [10] are involved in the anxiolytic effect of PFE, especially during long-term administration.
On the other hand, we previously found that the same PFE material as this study enhances the expression of clock genes such as period (Per) 2 in mouse liver and fibroblasts [12] . Based on these reports, we considered that PFE might influence sleep and emotions in humans, thus we conducted a clinical trial in healthy Japanese adults to investigate this possibility.
MATERIALS AND METHODS

Participants
All subjects were recruited from August 8 to September 30, 2017 through the Go106 website (https://www.go106.jp/) operated by ORTHOMEDICO Inc. (Tokyo, Japan). The inclusion criteria were healthy Japanese adults (male or female) with disturbance of their life rhythm or lack of motivation when engaging in their job or housework. Exclusion criteria were as follows.
1) Current or previous cancer, heart failure, or myocardial infarction.
2) Current treatment for arrhythmia, hepatitis, nephritis, rheumatoid arthritis, cerebrovascular disease, diabetes, hyperlipidemia, hypertension, or other chronic diseases.
3) Current use of medications or dietary supplements. 4) Experienced allergic reaction to foods related to passionflower or medicines. 5) Persons with hay fever, house dust allergy, or asthma. 6) Pregnancy, lactation, or expected/planned pregnancy during the study period. 7) Subjects currently participating in another clinical trial or who had participated within the previous 3 months. 8 ) Subjects determined to be inappropriate for the study for other reasons by the attending physician.
Sixty-four subjects with relatively low mental component summary (MCS) scores in the Japanese version of Medical Outcomes Study Short-Form 36-Item (SF-36) Health Survey [13] were selected after they were confirmed to be suitable for the study by a physician (Fig.   1 ). Then, the allocation controller, who was not directly involved in this study, allocated 22 subjects into 2 groups, using add-in software for Microsoft Excel (StatLight #11, Yukms Co.
Ltd., Kanagawa, Japan). The allocation was based on the SF-36 MCS score [mean and standard deviation (SD)], male/female ratio, and age in an approximately 1:1 ratio. The subjects were asked to avoid excessive eating and drinking and to maintain a regular lifestyle during the study period. One day before testing, subjects were required to avoid excessive drinking of alcohol and hard exercise, including a 6 hour fast, with the exception of water, prior to blood collection. 
Preparation and allocation of test articles
The test samples (indistinguishable brown capsules containing either PFE or placebo) were provided by Oryza Oil & Fat Chemical Co., Ltd. as hard capsules. The PFE capsules contained 100 mg of Passionflower Extract-P (standardized passionflower extract powder with 3.0% total flavonoids, including 0.90% isovitexin, 0.27% isovitexin O-glucoside, 0.39% isoschaftoside, and 0.24% homoorientin) and 100 mg of dextrin. Passionflower Extract-P was consisting of 60% PFE, 38% dextrin, and 2% fine silicon dioxide. The placebo capsules contained 196 mg of dextrin and 4 mg of fine silicon dioxide. Information about the allocation was strictly protected by third-party study allocation controllers not directly involved in the study, and this information was not disclosed to any other party until the subjects for analysis were determined at a clinical conference after study completion.
Study protocol
This randomized, placebo-controlled, double-blind, parallel-group study was carried out at Takara Clinic (Medical Corporation Seishinkai, Tokyo, Japan), and statistical analysis was performed by ORTHOMEDICO Inc. The protocol was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000028622). Subjects took two appropriate capsules (either placebo or PFE) daily within 1 hr before going to sleep for 12 weeks. All subjects recorded a daily report including capsule ingestion, lifestyle, urination, menstruation (only women), and implementation of questionnaire.
Following examination items were conducted baseline and 6 and 12 weeks after intake.
The SF-36 Health Survey was used to assess the primary outcomes and was completed before treatment and after 6 and 12 weeks of intake. The SF-36 is shown in Table 1 . Answer sheets were processed according to the manual, [14] and scores from 0 to 100 were calculated for the domains of physical functioning, role-physical, bodily pain, general health perception, vitality, social functioning, role-emotional, and mental health. Furthermore, these categories divided into physical component summary (PCS), mental component summary (MCS), and role/social component summary (RCS) and were calculated. The higher value indicates the better health condition. The Oguri-Shirakawa-Azumi (OSA) sleep score was used to assess the sleep quality as secondary outcomes [15] . The questionnaire covers items such as remaining fatigue, concentration ability, deepness of sleep, relaxing, dullness, appetite, dozing off, clearness of thought, nightmares, quality of sleep, feelings, dreaming, waking at night, answering ability, sleeping time, and deepness of sleep. The participant gave a score for each item, based on how if that statement was true or false. We evaluated the following 5 factors: sleepiness on rising (Factor I), initiation and maintenance of sleep (Factor II), frequent dreaming (Factor III), feeling of refreshment (Factor IV), and sleep length (Factor V).
Laboratory tests
Analysis of blood and urine was performed by LSI Medience Corporation (Tokyo, Japan). All examination items were conducted at a baseline and after 6 and 12 weeks of intake. A venous blood sample was collected from an arm vein and the following tests were performed for assessment of safety.
Hematology components were as follows: red blood cell count, leukocyte count, hemoglobin, hematocrit, platelet count, mean cell volume (MCV), mean cell hemoglobin (MCH), and mean cell hemoglobin concentration (MCHC).
Biochemical components were the following: total protein, total bilirubin, urea nitrogen, creatinine, uric acid, total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglyceride, hemoglobin (Hb) A1c, blood glucose, alkaline phosphatase (ALP), creatinine kinase (CK), aspartate aminotransferase (AST), alanine transaminase (ALT), -glutamyltransferase (-GTP), amylase, lactate dehydrogenase (LDH), Na, K, Cl, Ca, Fe, and inorganic phosphorus (IP).
In addition, urine samples were collected for qualitative evaluation including protein, glucose, urobilinogen, bilirubin, ketone bodies, pH and occult blood.
Ethics, adherence, and compliance
This study was performed according to the Declaration of Helsinki (2013 revision), and was carried out in conformity with ethical considerations. This protocol was approved by the Ethics Committee of Takara Clinic (Medical Corporation Seishinkai, Tokyo, Japan) on August 7, 2017 (Approved ID: 1708-1703-OY01-01-TC), and substantial deviation from the protocol required authorization by the committee. All subjects received a full explanation about the protocol and purpose of the study before giving consent for participation. No subject was part of sponsor or funder companies.
Statistical analysis
Primary and secondary outcomes are reported as the median and interquartile range. The MannWhitney U-test was used for comparisons between the placebo group and the PFE group. The results of the physical examination and blood tests are reported as the mean and SD. The paired student's t-test was used for evaluation of the significance of differences between, before, and after ingestion of the test sample. The χ 2 -test was used for urinalysis parameters, with normal
and abnormal values being coded as "1" and "0", respectively. We set the significance level at 5% with no adjustment for multiple comparisons. SPSS (Ver. 23.0, Japan IBM) or Microsoft
Excel 2013 was used for statistical evaluation.
RESULTS
Study performance
The study was performed from October 23, 2017 to January 20, 2018. During the study period, one subject in the PFE (200 mg) group and 2 subjects in the placebo group withdrew from the study for personal reasons. In addition, one subject was excluded from the analysis in the PFE (200 mg) group because of violation of compliance. Analysis of MCS data, showed that changes of the values exceeded 2.5 SD in 2 subjects from the placebo group. These subjects were excluded from analysis in the placebo group of SF-36. Accordingly, 20 subjects (5 male, 15 female, 44.5 ± 11.5 years) were available for analysis of both, SF-36 and the OSA sleep inventories in the PFE (200 mg) group. While, 18 (5 male, 13 female, 38.9 ± 10.8 years) and 20 subjects (5 male, 15 female, 38.5 ± 10.4 years) were respectively available for SF-36 and OSA sleep inventory analysis in the placebo group. Table 2 shows the physical profile of the subjects included in analysis. Body fat ratio (%) 22.9 ± 6.2 24.5 ± 6.7 23.2 ± 6.1 23.9 ± 6.9
Data are represented as the mean ± SD (n = 20). There were no significant differences between the placebo group and the PFE (200 mg) group. Table 3 lists the outcome of SF-36. After 6 weeks, changes of RCS, social functioning, and role-emotional were significantly larger in the PFE (200 mg) group compared with the placebo group (P = 0.008, P = 0.027, P < 0.050, respectively). Similarly, changes of MCS and vitality after 12 weeks were significantly larger in the PFE (200 mg) group than the placebo group (P = 0.048, P = 0.022, respectively). There was also a significant difference in the absolute value of vitality (P = 0.045).
SF-36 parameters
OSA sleep inventory
As shown in Table 4 , the OSA sleep inventory scores did not demonstrate any significant differences between the two groups for any sleep parameters at any time of assessment. Data are represented as the mean ± SD (n = 20 in both groups). Daggers denote significant differences from before PFE or placebo ingestion at †: p < 0.05, † †: p < 0.01.
Laboratory data and adverse effects
The blood pressure, pulse rate, and hematological components are listed in Table 5 . In the placebo group, the hematocrit and MCV were significantly increased at 12 weeks compared with the initial values, but there were no significant changes in the PFE group. With regard to biochemical components (Tables 6a and 6b) , total protein and Ca decreased slightly within reference ranges after ingestion of PFE for 12 weeks, while there was a significant increase of LDL-cholesterol, HDL-cholesterol, blood glucose, and amylase. However, these changes were all within reference ranges. Urinalysis parameters showed no changes in either group (Table 7) . 
DISCUSSION:
Previous clinical studies of passionflower have shown that it is effective for suppressing preoperative anxiety when a single dose was administered before surgery [1] [2] [3] 5] . While these studies evaluated the acute effect of passionflower in patients, the current study demonstrated that PFE improved MCS, RCS, social functioning, role-emotional, and vitality in healthy subjects performing shift work or with moderate anxiety related to their job/housework. These parameters were composed of mental factors [13] . PFE ameliorated anxiety due to unhealthy lifestyle or daily tasks. In addition, this effect of PFE was demonstrated to persist for several months. In a previous long-term intervention study, Gibbert et al. [16] administered PFE for 12 weeks and evaluated the effect on resistance to stress and QOL in patients suffering from nervous restlessness. They found that PFE improved resilience and QOL, corresponding well with our results. Regarding the anxiolytic mechanism of passionflower, PFE has been reported to inhibit GABA uptake into rat cortical synaptosomes and binding of GABA analogs to the GABA receptor [17] .
Flavonoids and an alkaloid (halmine), have been reported as promising active compounds in PFE [8] . The PFE used in our study had a standardized flavonoid content, including 6 flavonoid glycosides, and did not contain halmine. Therefore, flavonoids may play a major role in the anxiolytic effect of PFE.
Investigation of sleep quality showed that PFE did not affect the OSA sleep score, even though it was given orally just before sleep, and only improved diurnal psychological function.
The target subjects of this study did not have sleep disorders. If PFE had been evaluated in subjects with sleep problems, it may have improved sleep quality, as reported by Ngan et al. [6] .
CONCLUSIONS
This study demonstrated that intake of PFE (200 mg/day for 12 weeks) ameliorated mental anxiety in healthy subjects associated with irregular shift work and routine daily tasks.
Therefore, PFE may be useful for improving the quality of life. Furthermore, the intake of PFE was found to be safe under the conditions of the study. 
